Pharmacogenetics and pharmacogenomics

Pediatric Clinics of North America

Volumn 48, Issue 3, 2001, Pages 765-782

  Leeder, J Steven ^b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CODEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; DIAZEPAM; DICLOFENAC; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IBUPROFEN; IMIPRAMINE; IRBESARTAN; LOSARTAN; OMEPRAZOLE; PHENYTOIN; SERTRALINE; TETRAHYDROCANNABINOL; THEOPHYLLINE; TOLBUTAMIDE; TORASEMIDE; UNINDEXED DRUG; WARFARIN;

CHILD DEVELOPMENT; DIET; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSFORMATION; HUMAN; INFECTION; INTENSIVE CARE; PHARMACOGENETICS; PHENOTYPE; POLLUTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035016127     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0031-3955(05)70338-2     Document Type: Review

References (87)

1. Maturation of caffeine elimination in infancy
2. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
3. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4
4. Geographical/interracial differences in polymorphic drug oxidation
5. Allelic and functional variability of cytochrome P4502C9
6. Phenytoin elimination in newborns
7. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation
8. Population pharmacokinetics of midazolam in neonates
9. Human cytochrome P450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines
10. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
11. Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults
12. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient
13. Nomenclature for human CYP2D6 alleles
14. Glucuronidation in humans: Pharmacogenetic and developmental aspects
15. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity
16. Pharmacogenomics: Translating functional genomics into rational therapeutics
17. Association of CYP3A4 genotype with treatment-related leukemia
18. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva
19. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
20. Optimization of cytochrome P450 2D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
21. Biochemistry and molecular biology of the human CYP2C subfamily
22. Allelic variants of human cytochrome P4502C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereospecificity and prochiral selectivity of the wild-type and I359L mutant forms
23. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver
24. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
25. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients
26. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
27. The use of caffeine for enzyme assays: A critical appraisal
28. Pharmacokinetic studies in pediatric patients: Clinical and ethical considerations
29. Human liver carbamazepine metabolism: Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation
30. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
31. CYP3A gene expression in human gut epithelium
32. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence
33. Alterations in theophylline metabolism during the first year of life
34. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity
35. Expression of CYP3A in the human liver: Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
36. The effect of age, gender, and sexual maturation on the caffeine breath test
37. Delay in caffeine elimination in breast-fed infants
38. Acquisition of CYP2D6 and CYP3A activities in the first year of life
39. Phenytoin metabolism in infants following intravenous and oral administration
40. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia
41. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-Mercaptopurine dosage strategies
42. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant
43. The UDP glucuronosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
44. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
45. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population: Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs
46. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
47. Polymorphic thiopurine methyltransferase activity in erythrocytes is indicative of activity tn leukemic blasts from children with acute lymphoblastic leukemia
48. Genotype or phenotype: The definition of a pharmacogenetic polymorphism
49. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma
50. Acetaminophen elimination kinetics in neonates, children, and adults
51. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans
52. Theophylline disposition in infancy
53. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms
54. Morphine glucuronidation in human fetal and adult liver
55. First-pass metabolism of midazolam by the human intestine
56. The pharmacokinetics of midazolam in paediatric patients
57. The hypoalagesic effect of tramadol in relation to CYP2D6
58. Carbamazepine and its 10,11-epoxide in children and adults with epilepsy
59. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
60. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
61. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
62. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults: Influence of age and phenobarbitone comedication
63. Glutathione S-transferases, structure, regulation, and therapeutic implications
64. CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: Evidence for an allelic variant with altered catalytic activity
65. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
66. Morphine pharmacokinetics and pain assessment in premature newborns
67. The pharmacogenetics of codeine hypoalgesia
68. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter
69. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population
70. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
71. Genetic analysis of the human cytochrome P450 CYP2C9 locus
72. The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism
73. Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties, liver erythrocyte correlation and presence of isozymes
74. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
75. Caffeine as a probe for CYP1A2 activity: Potential influence of renal factors on urinary phenotypic trait measurements
76. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
77. Expression of CYP2D6 in developing human liver
78. Noninvasive tests of CYP3A enzymes
79. Chloramphenicol in the newborn infant: A physiologic explanation of its toxicity when given in excessive doses
80. Identification of a polymorphically expressed member of the human cytochrome P-450III family
81. The human hepatic cytochromes P450 involved in drug metabolism
82. Isolation and characterization of human fetal liver cytochrome P450HLp2: A third member of the P450III gene family
83. Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysis
84. Functional cytochrome P4503A isoforms in human embryonic tissues: Expression during organogenesis
85. Expression of functional cytochrome P4501A1 in human embryonic hepatic tissues during organogenesis
86. Chloramphenicol glucuronyl transferase: Assay, ontogeny and inducibility
87. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation